For the convenience of this study, NSCLC was broadly divided into two groups: one for patients with EGFR mutations and the other for patients with wildtype EGFR. The second group is an oversimplification and includes a gamut of different mutations including some driver mutations such as KRAS. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.